← All trials
NCT04850950
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 26, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Apr 20, 2021
- Last posted
- Apr 23, 2021
- Enrollment
- 240
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Zhengzhou UniversityLead sponsor
- Zhengzhou UniversityReponsible party - principal investigator
- Zhengzhou UniversityOverall official - principal investigator
- Nanjing UniversityCollaborator
- Nanyang Medical CollegeCollaborator
- Jiao Tong UniversityCollaborator
- Shandong Provincial HospitalCollaborator
- Nanyang Central HospitalCollaborator
- Xinyang Central HospitalCollaborator
- Luoyang Central HospitalCollaborator
- National Natural Science Foundation of ChinaCollaborator
- Yan'an University Affiliated HospitalCollaborator
- The Sixth People's Hospital of ZhengzhouCollaborator
- Henan Provincal People's HospitalCollaborator
- Fifth People's Hospital of AnyangCollaborator
- Sixth People's Hospital of KaifengCollaborator
- Luohe Central HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.